Skip to content
Ventavis(iloprost)
Ventavis (iloprost) is a small molecule pharmaceutical. Iloprost was first approved as Ventavis on 2003-09-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin D2 receptor, thromboxane A2 receptor, prostaglandin F2-alpha receptor, and prostaglandin E2 receptor EP1 subtype.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Ventavis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iloprost
Tradename
Company
Number
Date
Products
VENTAVISActelionN-021779 RX2005-12-08
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ventavisNew Drug Application2021-03-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary hypertensionEFO_0001361D006976I27.20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AC: Platelet aggregation inhibitors excl. heparin
B01AC11: Iloprost
HCPCS
Code
Description
Q4074
Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms
Clinical
Clinical Trials
84 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary hypertensionD006976EFO_0001361I27.20211721231
Pulmonary arterial hypertensionD0000810291341816
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.93126
Peripheral arterial diseaseD058729EFO_0004265112
HypertensionD006973EFO_0000537I1011
Heart failureD006333EFO_0003144I5011
SarcoidosisD012507EFO_0000690D80-D8911
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory distress syndromeD012128EFO_1000637J8022115
Systemic sclerodermaD012595EFO_0000717M34224
Septic shockD012772A48.3223
Pulmonary fibrosisD011658J84.10212
Chronic renal insufficiencyD051436N18111
Balloon angioplasty coronaryD015906EFO_0003951111
Coronary angiographyD017023111
Raynaud diseaseD011928EFO_1001145I73.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.901236
Respiratory insufficiencyD012131HP_0002093J96.9133
Congenital heart defectsD006330HP_0001627Q24.91112
Covid-19D000086382U07.122
ArteriosclerosisD001161EFO_0009086I7011
Arterial occlusive diseasesD001157EFO_000908511
PneumoniaD011014EFO_0003106J1811
Healthy volunteers/patients111
Shoulder fracturesD012784S42.9111
Multiple organ failureD009102EFO_100137311
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute lung injuryD055371EFO_000461011
AsthmaD001249EFO_0000270J4511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Eisenmenger complexD004541I27.8311
Coronary artery diseaseD003324I25.111
Pulmonary infarctionD054060EFO_100140811
Type 2 diabetes mellitusD003924EFO_0001360E1111
Video-assisted thoracic surgeryD02077511
PregnancyD011247EFO_0002950Z33.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameILOPROST
INNiloprost
Description
Iloprost is a carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension. It has a role as a platelet aggregation inhibitor and a vasodilator agent. It is a monocarboxylic acid, a secondary alcohol and a carbobicyclic compound.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O
Identifiers
PDB
CAS-ID78919-13-8
RxCUI
ChEMBL IDCHEMBL494
ChEBI ID63916
PubChem CID5311181
DrugBankDB01088
UNII IDJED5K35YGL (ChemIDplus, GSRS)
Target
Agency Approved
PTGIR
PTGIR
Organism
Homo sapiens
Gene name
PTGIR
Gene synonyms
PRIPR
NCBI Gene ID
Protein name
prostacyclin receptor
Protein synonyms
PGI receptor, PGI2 receptor, prostaglandin I2 (prostacyclin) receptor (IP), Prostaglandin I2 receptor, Prostanoid IP receptor
Uniprot ID
Mouse ortholog
Ptgir (19222)
prostacyclin receptor (Q52KE5)
Alternate
PTGER4
PTGER4
PTGER2
PTGER2
PTGER3
PTGER3
PTGDR
PTGDR
TBXA2R
TBXA2R
PTGFR
PTGFR
PTGER1
PTGER1
Organism
Homo sapiens
Gene name
PTGER4
Gene synonyms
PTGER2
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP4 subtype
Protein synonyms
PGE receptor, EP4 subtype, PGE2 receptor EP4 subtype, prostaglandin E receptor 4 (subtype EP4), Prostanoid EP4 receptor
Uniprot ID
Mouse ortholog
Ptger4 (19219)
prostaglandin E2 receptor EP4 subtype (P32240)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,853 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,131 adverse events reported
View more details